FDA warns against compound semaglutide for diabetes and weight loss

The FDA has issued a warning urging people to avoid using off-brand or compound formulations of the popular semaglutide drugs Ozempic, Wegovy and Rybelsus. Semaglutide drugs such as Ozempic, Wegovy and Rybelsus have become the subject of a global shortage, with demand for the trending drugs outstripping supply. As a result, some people have turned to compound pharmacies for versions of diabetes and weight loss drugs. Now the FDA is warning consumers that these off-label versions could be potentially dangerous. In a statement released May 31 titled Semaglutide-Containing Drugs Marketed…

Read More